Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome


Creative Commons License

YETER H. H. , DERİCİ Ü., Arinsoy T., ALTOK K., ERTEN Y., GÜZ G.

ROMANIAN JOURNAL OF INTERNAL MEDICINE, vol.60, no.1, pp.56-65, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 60 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.2478/rjim-2021-0034
  • Journal Name: ROMANIAN JOURNAL OF INTERNAL MEDICINE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, MEDLINE, Directory of Open Access Journals
  • Page Numbers: pp.56-65
  • Keywords: atypical hemolytic uremic syndrome, eculizumab, therapeutic plasma exchange, discontinuation, prognosis, MANAGEMENT, CONSENSUS, DIAGNOSIS, OUTCOMES
  • Gazi University Affiliated: Yes

Abstract

Introduction: To evaluate the effect of therapeutic plasma exchange(TPE) and eculizumab on hematological and renal survival in atypical hemolytic uremic syndrome(aHUS). Additionally, to examine the reliability of discontinuation of eculizumab treatment.